VERTEX PHARMACEUTICALS INC / MA

For the period ended Sep 30, 2026. Filed Nov 3, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 3, 2026

VRTX$550.87+0.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of

Condensed Consolidated Statements of Income

(unaudited; in millions, except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Revenues:
Product revenues, net	$3,440.8	$3,076.4	$9,761.6	$8,780.6
Other revenues	—	—	—	30.7
Total revenues	3,440.8	3,076.4	9,761.6	8,811.3
Costs and expenses:
Cost of sales	526.1	414.8	1,408.1	1,185.3
Research and development expenses	1,320.6	977.7	3,276.0	2,935.8
Acquired in-process research and development expenses	40.6	54.5	62.5	76.5
Selling, general and administrative expenses	844.1	445.1	1,920.0	1,266.1
Intangible asset impairment charge	—	—	—	379.0
Change in fair value of contingent consideration	(3.5)	(1.9)	(2.9)	1.2
Total costs and expenses	2,727.9	1,890.2	6,663.7	5,843.9
Income from operations	712.9	1,186.2	3,097.9	2,967.4
Interest income	118.4	125.7	360.1	369.0
Interest expense	(36.0)	(3.3)	(42.3)	(10.0)
Other (expense) income, net	(11.9)	(9.8)	12.4	(14.2)
Income before provision for income taxes	783.4	1,298.8	3,428.1	3,312.2
Provision for income taxes	129.8	215.9	643.3	550.1
Net income	$653.6	$1,082.9	$2,784.8	$2,762.1
Net income per common share:
Basic	$2.58	$4.24	$10.98	$10.77
Diluted	$2.56	$4.20	$10.90	$10.68
Shares used in per share calculations:
Basic	253.5	255.6	253.7	256.4
Diluted	255.2	257.6	255.5	258.6

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.